My watch list  


Phospholipidosis is a lipid storage disorder in which excess phospholipids accumulate within cells. Drug-induced phospholipidosis is an adverse drug reaction that occurs with many cationic amphiphillic drugs. While the mechanism is not truly understood, four possible mechanisms have been proposed, outlined below:

  • The drug may inhibit phospholipases, rendering the cell unable to break down excess phospholipids. This is the currently favored view, resulting from drug-phospholipid complex formation.
  • Increased synthesis of phospholipids within the cell.
  • Binding of the drug to phospholipids, preventing phospholipases from breaking down these drug-phospholipid complexes: a build-up of phospholipids bound to the drug yields results similar to a drug depot, with the possibility of decreased metabolism of drug and a later increase in exposure as the drug is released from the depot, or a disruption in cell function due to increased cytoplasmic space occupied through phospholid accumulation.
  • Breakdown of the lipids by the drug inducing lipid biosynthesis (See Baciu et al. 2006} .

A major concern for drug regulatory agencies is drug-induced phospholipidosis occurring in hepatocytes, kidneys, and lungs, which causes failure of liver, kidney, and respiratory function.

External links

  • Biophysical screen for the prediction of risk for drug-induced phospholipidosis
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Phospholipidosis". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE